PL1902017T3 - Przeciwwirusowe związki acyloguanidynowe - Google Patents
Przeciwwirusowe związki acyloguanidynoweInfo
- Publication number
- PL1902017T3 PL1902017T3 PL06741271T PL06741271T PL1902017T3 PL 1902017 T3 PL1902017 T3 PL 1902017T3 PL 06741271 T PL06741271 T PL 06741271T PL 06741271 T PL06741271 T PL 06741271T PL 1902017 T3 PL1902017 T3 PL 1902017T3
- Authority
- PL
- Poland
- Prior art keywords
- antiviral
- acylguanidine compounds
- acylguanidine
- compounds
- antiviral acylguanidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005903360A AU2005903360A0 (en) | 2005-06-24 | Anti-viral compounds and methods | |
| PCT/AU2006/000880 WO2006135978A1 (en) | 2005-06-24 | 2006-06-23 | Antiviral compounds and methods |
| EP06741271.8A EP1902017B1 (en) | 2005-06-24 | 2006-06-23 | Antiviral acylguanidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1902017T3 true PL1902017T3 (pl) | 2014-08-29 |
Family
ID=37570036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06741271T PL1902017T3 (pl) | 2005-06-24 | 2006-06-23 | Przeciwwirusowe związki acyloguanidynowe |
| PL13197255T PL2826770T3 (pl) | 2005-06-24 | 2006-06-23 | Przeciwwirusowe związki acyloguanidynowe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13197255T PL2826770T3 (pl) | 2005-06-24 | 2006-06-23 | Przeciwwirusowe związki acyloguanidynowe |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8669280B2 (pl) |
| EP (2) | EP2826770B1 (pl) |
| JP (2) | JP5373392B2 (pl) |
| KR (2) | KR20140072101A (pl) |
| CN (2) | CN103274970B (pl) |
| AU (1) | AU2006261593B2 (pl) |
| BR (2) | BRPI0612309B8 (pl) |
| CA (1) | CA2612403C (pl) |
| DK (2) | DK2826770T3 (pl) |
| ES (2) | ES2710662T3 (pl) |
| NZ (3) | NZ596107A (pl) |
| PL (2) | PL1902017T3 (pl) |
| PT (2) | PT2826770T (pl) |
| SG (1) | SG163517A1 (pl) |
| WO (1) | WO2006135978A1 (pl) |
| ZA (1) | ZA200800256B (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1646371A4 (en) * | 2003-06-26 | 2010-09-22 | Biotron Ltd | ANTIVIRAL COMPOSITIONS AND METHODS |
| US8669280B2 (en) * | 2005-06-24 | 2014-03-11 | Biotron Limited | Antiviral compounds and methods |
| PH12012502343A1 (en) | 2007-05-23 | 2013-06-17 | Siga Tech Inc | Antiviral drugs for treatment or prevention of dengue infection |
| AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
| ES2614269T3 (es) * | 2007-08-03 | 2017-05-30 | Biotron Limited | Procedimientos y composiciones antivíricas frente a la hepatitis C |
| EP2177505A4 (en) * | 2007-08-10 | 2011-08-31 | Astellas Pharma Inc | BICYCLIC ACYLGUANIDINE DERIVATIVE |
| US20120041036A1 (en) * | 2009-02-09 | 2012-02-16 | Isao Kinoyama | Substituted acylguanidine derivatives (as amended) |
| EP2394987A4 (en) * | 2009-02-09 | 2012-09-05 | Astellas Pharma Inc | ACYLGUANIDINDERIVAT |
| TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| US9126106B1 (en) | 2010-11-05 | 2015-09-08 | Wms Gaming, Inc. | Promotional content coordination in wagering game machines |
| WO2012083170A1 (en) * | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| DK3349758T3 (da) | 2015-09-16 | 2022-06-13 | Gilead Sciences Inc | Fremgangsmåder til behandling af arenaviridae-virusinfektioner |
| BR112019016316A2 (pt) * | 2017-02-08 | 2020-03-31 | Biotron Limited | Métodos para o tratamento da influenza |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| MX2022006274A (es) * | 2019-11-26 | 2022-10-13 | Biotron Ltd | Metodos de tratamiento de la infeccion por vih-1. |
| KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| EP4157272B1 (en) | 2020-05-29 | 2025-07-02 | Gilead Sciences, Inc. | Remdesivir for the treatment of viral infections |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| TWI925033B (zh) | 2020-10-16 | 2026-05-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| US12427150B2 (en) | 2021-05-26 | 2025-09-30 | Gilead Sciences, Inc. | Phospholipid formulations of 1′-cyano substituted carba-nucleoside analogs |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| AU2022399231A1 (en) * | 2021-11-24 | 2024-05-23 | Biotron Limited | Methods of treating sars-cov-2 infection |
| JP2025508943A (ja) | 2022-03-02 | 2025-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | ウイルス感染症の治療のための化合物及び方法 |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| CN118843629A (zh) | 2022-03-03 | 2024-10-25 | 吉利德科学公司 | 抗病毒化合物及其制备和使用方法 |
| US20230382940A1 (en) | 2022-03-03 | 2023-11-30 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| JPWO2023167055A1 (pl) * | 2022-03-03 | 2023-09-07 | ||
| WO2023239665A1 (en) | 2022-06-06 | 2023-12-14 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
| EP4547334A1 (en) | 2022-06-29 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| CN115260100B (zh) * | 2022-08-08 | 2023-12-12 | 赛诺瑞生物医药技术(无锡)有限公司 | 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024173458A1 (en) | 2023-02-16 | 2024-08-22 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2025049699A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250084088A1 (en) | 2023-08-31 | 2025-03-13 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| EP4774275A1 (en) | 2023-09-06 | 2026-07-15 | Gilead Sciences, LLC | Solid forms of a nucleoside analogue and uses thereof |
| KR20260079626A (ko) | 2023-09-28 | 2026-06-02 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2734904A (en) | 1956-02-14 | Xcxnhxc-nh | ||
| US4251545A (en) * | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
| US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
| JPH0218632A (ja) | 1988-07-07 | 1990-01-22 | Matsushita Electric Ind Co Ltd | 論理ゲート評価装置と論理ゲート評価方法 |
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4328869A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4421536A1 (de) * | 1994-06-20 | 1995-12-21 | Hoechst Ag | Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JPH08225513A (ja) * | 1994-12-21 | 1996-09-03 | Kanebo Ltd | ナフトイルグアニジン誘導体 |
| DE19518796A1 (de) | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19527305A1 (de) | 1995-07-26 | 1997-01-30 | Hoechst Ag | Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19606355A1 (de) * | 1996-02-12 | 1997-08-14 | Schering Ag | Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung |
| DE19621483A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| AUPO545297A0 (en) | 1997-03-04 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| US20030113352A1 (en) * | 2001-12-14 | 2003-06-19 | The Regents Of The University Of California | Neutralization of stratum corneum to treat hyperkeratotic skin lesions |
| CA2551169A1 (en) | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| KR20120045062A (ko) * | 2003-03-31 | 2012-05-08 | 가부시키가이샤 아루떼꾸 우에노 | 혈관 과투과 질환의 치료방법 |
| EP1646371A4 (en) | 2003-06-26 | 2010-09-22 | Biotron Ltd | ANTIVIRAL COMPOSITIONS AND METHODS |
| US20070099968A1 (en) | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
| US8669280B2 (en) * | 2005-06-24 | 2014-03-11 | Biotron Limited | Antiviral compounds and methods |
| ES2320042T3 (es) * | 2005-10-19 | 2009-05-18 | F. Hoffmann-La Roche Ag | Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida. |
| JP5727842B2 (ja) | 2011-04-12 | 2015-06-03 | 日野自動車株式会社 | 車両のインストルメントパネル構造 |
| KR101331921B1 (ko) * | 2013-01-16 | 2013-11-21 | 에스케이플래닛 주식회사 | 영유아의 안전을 위한 스마트 인터랙션 서비스를 제공하는 장치 및 방법, 이를 이용한 시스템 |
-
2006
- 2006-06-23 US US11/922,281 patent/US8669280B2/en active Active
- 2006-06-23 PL PL06741271T patent/PL1902017T3/pl unknown
- 2006-06-23 NZ NZ596107A patent/NZ596107A/xx not_active IP Right Cessation
- 2006-06-23 KR KR1020147010199A patent/KR20140072101A/ko not_active Ceased
- 2006-06-23 PT PT13197255T patent/PT2826770T/pt unknown
- 2006-06-23 WO PCT/AU2006/000880 patent/WO2006135978A1/en not_active Ceased
- 2006-06-23 NZ NZ564398A patent/NZ564398A/en unknown
- 2006-06-23 ES ES13197255T patent/ES2710662T3/es not_active Expired - Lifetime
- 2006-06-23 PL PL13197255T patent/PL2826770T3/pl unknown
- 2006-06-23 AU AU2006261593A patent/AU2006261593B2/en not_active Expired
- 2006-06-23 CN CN201310097430.5A patent/CN103274970B/zh not_active Expired - Fee Related
- 2006-06-23 SG SG201004454-3A patent/SG163517A1/en unknown
- 2006-06-23 BR BRPI0612309A patent/BRPI0612309B8/pt active IP Right Grant
- 2006-06-23 BR BR122020006906A patent/BR122020006906B8/pt active IP Right Grant
- 2006-06-23 DK DK13197255.6T patent/DK2826770T3/en active
- 2006-06-23 ES ES06741271.8T patent/ES2491217T3/es not_active Expired - Lifetime
- 2006-06-23 EP EP13197255.6A patent/EP2826770B1/en not_active Expired - Lifetime
- 2006-06-23 DK DK06741271.8T patent/DK1902017T3/da active
- 2006-06-23 JP JP2008517277A patent/JP5373392B2/ja not_active Expired - Lifetime
- 2006-06-23 ZA ZA200800256A patent/ZA200800256B/xx unknown
- 2006-06-23 CA CA2612403A patent/CA2612403C/en not_active Expired - Lifetime
- 2006-06-23 KR KR1020087001886A patent/KR101419327B1/ko not_active Expired - Lifetime
- 2006-06-23 NZ NZ610715A patent/NZ610715A/en not_active IP Right Cessation
- 2006-06-23 PT PT67412718T patent/PT1902017E/pt unknown
- 2006-06-23 CN CN2006800226410A patent/CN101208297B/zh not_active Expired - Lifetime
- 2006-06-23 EP EP06741271.8A patent/EP1902017B1/en not_active Expired - Lifetime
-
2012
- 2012-09-24 JP JP2012209126A patent/JP5616410B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-05 US US14/071,870 patent/US9440926B2/en not_active Expired - Lifetime
-
2016
- 2016-09-12 US US15/262,075 patent/US10683263B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1902017E (pt) | Compostos e métodos antivirais | |
| AP2461A (en) | Antiviral compounds | |
| IL180758A0 (en) | Antiviral compounds | |
| AP2874A (en) | Antiviral compounds | |
| ZA200806756B (en) | Hetero-bycyclic antiviral compounds | |
| IL192002A0 (en) | Antiviral nucleosides | |
| IL186661A0 (en) | Heterocyclic antiviral compounds | |
| EP1939198A4 (en) | NEW ADENINE COMPOUND | |
| IL202623A0 (en) | Antiviral compounds | |
| EP2234623A4 (en) | ANTIVIRAL CONNECTIONS | |
| ZA201107667B (en) | Anti-viral compounds | |
| EP1893629A4 (en) | ANTIVIRAL CONNECTIONS | |
| GB0519245D0 (en) | Purine compounds | |
| GB0614034D0 (en) | Antiviral compounds | |
| AP2007004220A0 (en) | Motilide compounds | |
| EP1907385A4 (en) | LINKS | |
| ZA200701118B (en) | Antiviral compounds | |
| EP1867650A4 (en) | HYDROXYMETHYLBORVERBINDUNGEN | |
| GB0507201D0 (en) | New antiviral indolilydene analogues | |
| GB0518841D0 (en) | Novel antiviral strategy | |
| HK1114569A (en) | Antiviral compounds | |
| HK1115883A (en) | Antiviral compounds | |
| HK1117167A (en) | Antiviral compounds | |
| GB0516666D0 (en) | Antiviral compositions | |
| GB0506894D0 (en) | New anti-viral compounds |